Artivion, Inc.

Health Care
Medical/Dental Instruments
www.artivion.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.14B
PE -85
Debt $320.39M
Cash $53.46M
EV $1.41B
FCF $11.05M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$13.36M
EBIT	$38.87M
ROE	-5%
ROA	5%
FCF	$11.05M
Equity	$276.20M
Growth Stability	-2K%
PE	-85.32
PB	4.13
P/FCF	103.17
P/S	2.93
Price/Cash	0.05
Debt/Equity	1.16
Debt/FCF	29
Net Margins	-3%
Gross Margins	64%
Op. Margins	10%
Earnings CAGR	-1%
Sales Growth YoY	4%
Sales Growth QoQ	2%
Sales CAGR	10%
FCF CAGR	-2%
Equity CAGR	5%
Earnings Stability	0.02
Earnings Growth YoY	315%
Earnings Growth QoQ	622%

Sales CAGR 5Y	10%
FCF CAGR 5Y	11%
Equity CAGR 5Y	-2%
Earnings CAGR 3Y	10%
Sales CAGR 3Y	10%
FCF CAGR 3Y	137%
Equity CAGR 3Y	2%
Market Cap	$1.14B
Revenue	$388.54M
Assets	$789.10M
Total Debt	$320.39M
Cash	$53.46M
Shares Outstanding	41.68M
EV	1.41B
Earnings Score	6%
Moat Score	28%
Safety Score	39%
Final Score	24%
Working Capital	223.26M
Current Ratio	4.34
Gross Profit	$248.78M
Shares Growth 3y	2%
Equity Growth QoQ	-9%
Equity Growth YoY	-2%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Cryolife Inc is a registered with the U.S. Security and Exchange Commission and incorporated in the state of Florida. Cryolife Inc is primarely in the business of surgical & medical instruments & apparatus. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Cryolife Inc. Cryolife Inc is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures focused on aortic repair. The company has two reportable segments namely Medical devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue, On-X products, JOTEC products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix.

SEC Filings

Direct access to Artivion, Inc. (AORT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Artivion, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Artivion, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -1%

Stability 2%

loading chart...

Artivion, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Artivion, Inc..

Years

Calculation mode

= $96M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$11M	$11M	$11M	$10M	$10M	$9.9M	$9.7M	$9.5M	$9.3M	$9.1M	$8.9M	$89M
DCF		$9.8M	$8.8M	$7.8M	$6.9M	$6.2M	$5.5M	$4.9M	$4.3M	$3.9M	$3.4M	$34M
Value	$96M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	3%	6%	2%	-1%	1%	-7%	-5%	-6%	-9%	-3%	-3%
ROA	-	7%	1%	2%	3%	0%	1%	1%	1%	5%	5%
ROE	-	5%	1%	-1%	1%	-5%	-5%	-7%	-11%	-5%	-5%

Bad Net Margins (-3.44%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	5.78	55.07	55.46	28.93	59.78	-20.37	-22.33	27.51	29	29
Debt over Equity	-	0.37	0.83	0.83	0.79	0.92	1.06	1.11	1.11	1.16	1.16
Growth Stability	-	-	-	-47%	45%	-2K%	-	-	-	-	-2K%

Bad Debt/FCF ratio (29)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.16)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-2K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	24%	5%	39%	5%	-8%	18%	5%	13%	10%	10%
Earnings YoY growth	-	170%	-66%	-178%	-160%	-1K%	-11%	29%	60%	-56%	-
Equity YoY growth	-	35%	33%	-1%	4%	15%	-9%	-5%	-1%	-2%	-2%
FCF YoY growth	-	70%	-69%	-2%	89%	-35%	-411%	-10%	-180%	-3%	11%